Merck to Reduce Headcount by 1,100
News Sep 08, 2012
The efficiency measures are part of the company’s "Fit for 2018" business transformation program spanning all businesses and regions in order to secure Merck’s long-term competitiveness. Merck plans to eliminate around 1,100 of the 10,900 positions in Germany by the end of 2015. The positions will be reduced in a socially acceptable manner, mainly through voluntary-resignation and early retirement programs across all divisions and functions. As part of the agreement concerning the efficiency measures associated with the "Fit for 2018" program, Merck will refrain from forced redundancies until the end of 2017, with the exception of possible site closures and transfers that are still being assessed.
“We have had constructive discussions with Works Council members for the past several months and are happy to say that we now have a roadmap that will position Merck Germany in such a way that the company is prepared for the challenges we will face,” said Kai Beckmann, member of the Executive Board and responsible for Human Resources. “This agreement is a positive development for Merck’s future and a clear commitment to Germany. Now, we need to consistently implement the measures and continue moving ahead with the changes in our company.”
“For the Works Council, it is particularly important that there will be no forced redundancies in Darmstadt and Gernsheim through the end of 2017 and we were largely able to avoid outsourcing of jobs,” added Works Council Chairman Heiner Wilhelm.
The efficiency measures for Germany comprise more than 100 individual initiatives spanning all businesses and functions. Among others, several support functions across the divisions, such as logistics, will be reorganized. Outsourcing functions to external providers – a measure that had been considered – are not planned. The only exception are activities that are already partially being outsourced to third-party suppliers, such as routine jobs connected to the approval of drugs (Regulatory Affairs), or jobs that require considerable manual labor, such as certain blending and filling activities in production. This will affect around 100 jobs. These outsourcing plans are in line with Merck’s strategic approach as set out by the “Fit for 2018” program, which calls for production to be focused on core activities that generate high value.
In the area of financial services, specifically Merck Shared Services Europe GmbH (MSSE), it has been agreed to jointly leverage efficiencies. Merck will refrain from relocating MSSE abroad, a move that had been under review in recent months, at least until the end of 2015. The parties are confident that the defined targets can also be reached at the Darmstadt location.
The production of industrial salts in Lehrte, Germany, as well as the filling operations in Hohenbrunn, Germany, will be discontinued. A total of approximately 140 employees are working at the two sites. In the months ahead, the Works Council and Merck will consider various scenarios for the two sites.
Further cost savings will be realized by a reduction in personnel costs as the result of a restructuring of the compensation system. To strengthen the Darmstadt site within the framework of the “Fit for 2018” program, Merck also plans to invest a total of at least € 250 million at this location and other sites within Germany during the next two years. The Darmstadt site, as the global headquarters of the Merck Group, will be expanded further and, as a state-of-the-art production and research center, will be able to meet the highest competitive demands. A modern and up-to-date working environment, flexible organizational structures, and suitable workspaces in research and development should be able to drive innovation, retain talents and attract skilled professionals. Darmstadt is to be expanded to become an R&D center of excellence, with a tightly networked research and knowledge platform for both pharmaceuticals and chemicals.
Merck announced its global efficiency program, which spans all regions and businesses, at the end of February. The company has already begun implementation of some efficiency programs outside Germany in recent months. For example, Merck announced in April that the headquarters of its pharmaceutical division (Merck Serono) would be moved from Geneva to Darmstadt.
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
Comments | 0 ADD COMMENT
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018